Berlin

• A study to learn about how elinzanetant works and how safe it is in women having sleep disturbances associated with menopause Ended
  2023-504955-28-01 4 2024-03-14 Sleep disturbances associated with menopause
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• A trial of prednisolone in combination with SPI-62 in participants with polymyalgia rheumatica (PMR) Ended
  2023-507721-41-00 3 2024-03-11 polymyalgia rheumatica
• A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressure Ended
  2023-505499-32-00 5 2024-03-08 Uncontrolled hypertension (uTHN) defined as blood pressure that remain
• A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Pa … Ended
  2023-507534-24-00 9 2024-03-06 Chronic Inducible Urticaria
• A study to evaluate SAR441566 efficacy and safety in adults with rheumatoid arthritis Ended
  2023-503910-60-00 4 2024-03-05 Rheumatoid arthritis
• Study Drug vs Placebo as an “add on” treatment for Severe Community-Acquired Pneumonia. Ended
  2023-505985-28-01 4 2024-03-04 Severe Community-Acquired Pneumonia
• A Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Selnoflast in Participants with Moderate to Severe Asthma Ended
  2023-504304-29-00 3 2024-03-01 Moderate to Severe Asthma
• A Randomized, Placebo-Controlled, Double-Blind Study of XPro1595 in Patients with Early Alzheimer’s Disease with Biomarkers of Inflammation Ended
  2023-505396-71-00 4 2024-03-01 Early Alzheimer’s Disease with Biomarkers of Inflammation
• A study to test how well BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis (ClairaflyTM) Ended
  2022-502835-21-00 4 2024-02-23 cystic fibrosis bronchiectasis
• This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu … Ended
  2023-504800-28-00 3 2024-02-23 Chronic Inducible Urticaria
• A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight Ended
  2023-504792-24-00 3 2024-02-20 Obesity
• This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu … Ended
  2023-504799-94-00 4 2024-02-20 Chronic Spontaneous Urticaria
• A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple doses Ended
  2023-507882-24-00 1 2024-02-20 Inflammatory Gastrointestinal Disease
• A randomized, placebo-controlled, parallel-group, investigator- and participant-blinded Phase 2a study to investigate the efficacy, safety, … Ended
  2023-506741-34-00 4 2024-02-16 Atherosclerotic cardiovascular disease
• Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended
  2023-504346-66-00 4 2024-02-14 Dermatitis atopic
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)
• A study of how CagriSema works on appetite in people with excess body weight Ended
  2023-504782-23-00 3 2024-02-09 Obesity
• A trial to compare the efficacy and safety of aficamten (CK-3773274) compared with metoprolol succinate in adults with symptomatic hypertrop … Ended
  2023-504809-37-00 5 2024-02-07 Symptomatic Obstructive Hypertrophic Cardiomyopathy
• A trial to learn how baxdrostat affects the heartbeat in healthy participants Ended
  2023-506108-23-00 3 2024-02-06 Treatment-resistant hypertension
• Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis Ended
  2022-502997-18-00 3 2024-02-02 Atopic Dermatitis
• A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended
  2022-503013-32-00 4 2024-01-29 ER-positive/HER2-negative early breast cancer
• A study to evaluate efficacy and safety of SAR441566 in adults with plaque psoriasis Ended
  2023-503911-14-00 4 2024-01-25 Psoriasis

Showing 1,441–1,464 of 1,776 trials